Literature DB >> 2161702

Infusion of high doses of undiluted etoposide through central venous catheters during preparation for bone marrow transplantation.

R J Creger1, R M Fox, H M Lazarus.   

Abstract

We employed a new method to administer etoposide in high doses to 51 patients undergoing autologous bone marrow transplantation. Undiluted etoposide (20 mg/ml) was sterilely drawn into Luer-Lok plastic syringes, connected to IV extension tubing, and infused intravenously by a syringe pump over 3-4 hours. Patients received etoposide at doses ranging from 400 to 1600 mg/m2 per day (median dose: 800 mg). Total actual etoposide doses infused during the transplant period ranged from 2200 to 9000 mg. The infusion rate range was 4.1-13.4 mg/min. No episodes of hypotension, bronchospasm, or hemorrhagic cystitis were noted during or within 3 days of the etoposide infusion. In addition, no cracking of the infusion apparatus was observed in any of the 148 separate infusions. Serum bicarbonate concentrations fell significantly in 6 patients who received the higher etoposide doses. This procedure is superior to the standard method of etoposide drug delivery, since large doses of etoposide may be given without the concomitant administration of large volumes of fluid over short periods of time.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2161702     DOI: 10.3109/07357909009017542

Source DB:  PubMed          Journal:  Cancer Invest        ISSN: 0735-7907            Impact factor:   2.176


  3 in total

1.  Unaltered pharmacokinetics after the administration of high-dose etoposide without prior dilution.

Authors:  G Ehninger; B Proksch; H Schmidt; P Waidelich; B Eichel; R Dopfer
Journal:  Cancer Chemother Pharmacol       Date:  1991       Impact factor: 3.333

2.  Safety and efficacy of intraperitoneal injection of etoposide in oil suspension in mice with peritoneal carcinomatosis.

Authors:  J S Lee; T Takahashi; A Hagiwara; C Yoneyama; M Itoh; T Sasabe; S Muranishi; S Tashima
Journal:  Cancer Chemother Pharmacol       Date:  1995       Impact factor: 3.333

3.  Total body irradiation, etoposide, cyclophosphamide, and autologous peripheral blood stem-cell transplantation followed by randomization to therapy with interleukin-2 versus observation for patients with non-Hodgkin lymphoma: results of a phase 3 randomized trial by the Southwest Oncology Group (SWOG 9438).

Authors:  John A Thompson; Richard I Fisher; Michael Leblanc; Stephen J Forman; Oliver W Press; Joseph M Unger; Auayporn P Nademanee; Patrick J Stiff; Stephen H Petersdorf; Alexander Fefer
Journal:  Blood       Date:  2008-02-06       Impact factor: 22.113

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.